OHRP Profile
Ohr
Pharmaceuticals, Inc. (OHRP) is a biopharmaceutical company that
develops and commercializes novel therapies for the treatment of
ophthalmic diseases. The company's lead product candidate is
squalamine lactate ophthalmic solution, which is being developed as a
treatment for retinal diseases such as wet age-related macular
degeneration (AMD). Here's an extended company report for Ohr
Pharmaceuticals, Inc.:
Ohr Pharmaceuticals, Inc. was founded in
2008 and is headquartered in New York City. The company's core focus
is on developing and commercializing novel therapies for the treatment
of ophthalmic diseases. OHRP's lead product candidate, squalamine
lactate ophthalmic solution, is being developed as a treatment for
retinal diseases such as wet AMD, which is the leading cause of
blindness in people over the age of 65.
Squalamine lactate
ophthalmic solution is a novel therapeutic agent that works by
inhibiting the growth of abnormal blood vessels in the retina, which
is a key factor in the development of wet AMD. The drug has been
granted fast-track status by the U.S. Food and Drug Administration
(FDA) and is currently in phase 3 clinical trials.
In addition
to its lead product candidate, Ohr Pharmaceuticals has a pipeline of
other drug candidates for the treatment of various ophthalmic
diseases, including glaucoma and diabetic retinopathy. The company's
diverse pipeline of products allows it to serve a wide range of
patients with unmet medical needs.
As of March 18, 2023, Ohr
Pharmaceuticals had a market capitalization of approximately $10
million. The company's stock is traded on the NASDAQ exchange under
the ticker symbol OHRP.
Investing in Ohr Pharmaceuticals
involves significant risks, including the risk that the company's
products may not gain regulatory approval, the risk of increased
competition from other companies in the ophthalmic drug space, and the
risk of adverse side effects associated with the use of the company's
products.
In conclusion, Ohr Pharmaceuticals, Inc. is a
biopharmaceutical company that develops and commercializes novel
therapies for the treatment of ophthalmic diseases. The company's lead
product candidate, squalamine lactate ophthalmic solution, is being
developed as a treatment for wet AMD and has been granted fast-track
status by the FDA. Ohr Pharmaceuticals' diverse pipeline of products
allows it to serve a wide range of patients with unmet medical needs.
Investors should carefully consider the risks and potential benefits
of investing in Ohr Pharmaceuticals before making any investment
|
